1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Drugs In Development, 2022, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 6, 8, 2, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Diphtheria - Overview
- Diphtheria - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diphtheria - Therapeutics Assessment
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diphtheria - Companies Involved in Therapeutics Development
- Diphtheria - Drug Profiles
- Diphtheria - Dormant Projects
- Diphtheria - Discontinued Products
- Diphtheria - Product Development Milestones
- Featured News & Press Releases
- Apr 26, 2022: KM Biologics files DTaP-IPV-Hib vaccine in Japan
- Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi
- Apr 11, 2022: Notification of manufacturing and marketing approval application for pertussis/diphtheria/tetanus/inactivated polio/Hib combined vaccine (BK1310/MT-2355)
- Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)
- Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
- Feb 01, 2019: VaxForm receives a grant of $225,000 from National Science Foundation (NSF)
- Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Diphtheria, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Diphtheria - Pipeline by AIM Vaccine Co Ltd, 2022
- Diphtheria - Pipeline by Amogen Pharma Pvt Ltd, 2022
- Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Diphtheria - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
- Diphtheria - Pipeline by Biken Co Ltd, 2022
- Diphtheria - Pipeline by Biological E Ltd, 2022
- Diphtheria - Pipeline by BioNet-Asia Co Ltd, 2022
- Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Diphtheria - Pipeline by CanSino Biologics Inc, 2022
- Diphtheria - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
- Diphtheria - Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2022
- Diphtheria - Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
- Diphtheria - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Diphtheria - Pipeline by Emergent BioSolutions Inc, 2022
- Diphtheria - Pipeline by GC Biopharma Corp, 2022
- Diphtheria - Pipeline by KM Biologics Co Ltd, 2022
- Diphtheria - Pipeline by LG Chem Ltd, 2022
- Diphtheria - Pipeline by MassBiologics, 2022
- Diphtheria - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
- Diphtheria - Pipeline by Panacea Biotec Ltd, 2022
- Diphtheria - Pipeline by Sanofi, 2022
- Diphtheria - Pipeline by Serum Institute of India Pvt Ltd, 2022
- Diphtheria - Pipeline by Shantha Biotechnics Pvt Ltd, 2022
- Diphtheria - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
- Diphtheria - Pipeline by VaxForm LLC, 2022
- Diphtheria - Pipeline by Yunnan Watson Biotechnology Co Ltd, 2022
- Diphtheria - Pipeline by Zydus Lifesciences Ltd, 2022
- Diphtheria - Dormant Projects, 2022
- Diphtheria - Discontinued Products, 2022
- Number of Products under Development for Diphtheria, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AIM Vaccine Co Ltd
- Amogen Pharma Pvt Ltd
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Biken Co Ltd
- Biological E Ltd
- BioNet-Asia Co Ltd
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Kanghua Biological Products Co Ltd
- Chengdu Olymvax Biopharmaceuticals Inc
- Chongqing Zhifei Biological Products Co Ltd
- Emergent BioSolutions Inc
- GC Biopharma Corp
- KM Biologics Co Ltd
- LG Chem Ltd
- MassBiologics
- Novo Medi Sciences Pvt Ltd
- Panacea Biotec Ltd
- Sanofi
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Suzhou Weichao Biotechnology Co Ltd
- VaxForm LLC
- Yunnan Watson Biotechnology Co Ltd
- Zydus Lifesciences Ltd
